The University of Chicago Header Logo

Connection

Sarosh Rana to Pre-Eclampsia

Back to Details
This is a "connection" page, showing publications Sarosh Rana has written about Pre-Eclampsia.
Sarosh Rana
Connection Strength
24.758
Pre-Eclampsia
  1. Placental Biomarker Testing for Evaluation of Suspected Preeclampsia. Clin Chem. 2025 May 02; 71(5):548-558.
    View in: PubMed
    Score: 0.729
  2. Neonatal cost savings in hypertensive disorders of pregnancy: Economic evaluation of the sFlt-1/PlGF test with real world implementation of biomarkers. Pregnancy Hypertens. 2025 Mar; 39:101190.
    View in: PubMed
    Score: 0.714
  3. Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1/placental growth factor test for routine clinical evaluation of hospitalized women with hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2025 Apr; 232(4):385.e1-385.e21.
    View in: PubMed
    Score: 0.690
  4. Signs or symptoms of suspected preeclampsia - A retrospective national database study of prevalence, costs, and outcomes. Pregnancy Hypertens. 2024 Jun; 36:101124.
    View in: PubMed
    Score: 0.677
  5. Luteolin prevents TNF-a-induced NF-?B activation and ROS production in cultured human placental explants and endothelial cells. Placenta. 2024 01; 145:65-71.
    View in: PubMed
    Score: 0.661
  6. Patient and provider perception of home blood pressure monitoring kits. Pregnancy Hypertens. 2023 Dec; 34:33-38.
    View in: PubMed
    Score: 0.653
  7. Angiogenic Biomarkers for Preeclampsia in Clinical Setting: A New Era. Hypertension. 2023 10; 80(10):2029-2032.
    View in: PubMed
    Score: 0.652
  8. Bioflavonoid luteolin prevents sFlt-1 release via HIF-1a inhibition in cultured human placenta. FASEB J. 2023 08; 37(8):e23078.
    View in: PubMed
    Score: 0.645
  9. Reducing the Risk of Term Preeclampsia by Risk-Stratified Timing of Birth: Time to Deliver. Hypertension. 2023 05; 80(5):979-980.
    View in: PubMed
    Score: 0.633
  10. Association of fetal sex with angiogenic factors in normotensive and hypertensive pregnancy states. Pregnancy Hypertens. 2022 Aug; 29:108-115.
    View in: PubMed
    Score: 0.600
  11. Angiogenic Biomarkers for Risk Stratification in Women with Preeclampsia. Clin Chem. 2022 06 01; 68(6):771-781.
    View in: PubMed
    Score: 0.595
  12. Racial Differences in Readmissions in Hypertensive Disorders of Pregnancy. Reprod Sci. 2022 07; 29(7):2071-2078.
    View in: PubMed
    Score: 0.588
  13. Women's perspectives and attitudes towards the utility of angiogenic biomarkers in preeclampsia. Pregnancy Hypertens. 2022 Jun; 28:109-113.
    View in: PubMed
    Score: 0.587
  14. Racial Disparities in Diagnosis, Management, and Outcomes in Preeclampsia. Curr Hypertens Rep. 2022 04; 24(4):87-93.
    View in: PubMed
    Score: 0.586
  15. Prevalence and management of severe intrapartum hypertension in patients with preeclampsia at an urban tertiary care medical center. Pregnancy Hypertens. 2022 Mar; 27:87-93.
    View in: PubMed
    Score: 0.578
  16. Cost effectiveness of the sFlt1/PlGF ratio test as an adjunct to the current practice of evaluating suspected preeclampsia in the United States. Pregnancy Hypertens. 2021 Dec; 26:121-126.
    View in: PubMed
    Score: 0.571
  17. The interval between births and the risk of recurrent preeclampsia among predominantly high risk women in urban tertiary care center. Pregnancy Hypertens. 2021 Aug; 25:7-11.
    View in: PubMed
    Score: 0.554
  18. Real life outpatient biomarker use in management of hypertensive pregnancies in third trimester in a low resource SeTting: ROBUST study. Pregnancy Hypertens. 2021 Mar; 23:97-103.
    View in: PubMed
    Score: 0.537
  19. Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. Am J Obstet Gynecol. 2022 02; 226(2S):S1019-S1034.
    View in: PubMed
    Score: 0.532
  20. Evaluation of angiogenic factors in the decision to admit women with suspected preeclampsia. Pregnancy Hypertens. 2020 Jul; 21:124-131.
    View in: PubMed
    Score: 0.518
  21. Angiogenic Factor Estimation as a Warning Sign of Preeclampsia-Related Peripartum Morbidity Among Hospitalized Patients. Hypertension. 2019 04; 73(4):868-877.
    View in: PubMed
    Score: 0.478
  22. Preeclampsia: Pathophysiology, Challenges, and Perspectives Circ Res. 2019 03 29; 124(7):1094-1112.
    View in: PubMed
    Score: 0.478
  23. Association of antepartum blood pressure levels and angiogenic profile among women with chronic hypertension. Pregnancy Hypertens. 2018 Oct; 14:110-114.
    View in: PubMed
    Score: 0.459
  24. Angiogenic biomarkers in triage and risk for preeclampsia with severe features. Pregnancy Hypertens. 2018 Jul; 13:100-106.
    View in: PubMed
    Score: 0.451
  25. Abnormal mid-trimester cardiac strain in women with chronic hypertension predates superimposed preeclampsia. Pregnancy Hypertens. 2017 Oct; 10:251-255.
    View in: PubMed
    Score: 0.433
  26. Angiogenic Proteins: Can These Biomarkers Help to Prevent Maternal Deaths Related to Preeclampsia? Hypertension. 2017 03; 69(3):401-403.
    View in: PubMed
    Score: 0.411
  27. Circulating Antiangiogenic Factors and Myocardial Dysfunction in Hypertensive Disorders of Pregnancy. Hypertension. 2016 06; 67(6):1273-80.
    View in: PubMed
    Score: 0.390
  28. KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes. Hypertens Pregnancy. 2016 Aug; 35(3):330-45.
    View in: PubMed
    Score: 0.388
  29. Sequential plasma angiogenic factors levels in women with suspected preeclampsia. Am J Obstet Gynecol. 2016 Jul; 215(1):89.e1-89.e10.
    View in: PubMed
    Score: 0.384
  30. Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia. PLoS One. 2015; 10(5):e0126815.
    View in: PubMed
    Score: 0.365
  31. Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. Prenat Diagn. 2015 Apr; 35(4):386-93.
    View in: PubMed
    Score: 0.358
  32. Response to Carbillon L et al. letter titled; "The imbalance of circulating angiogenic/anti-angiogenic factors is mild or absent in obese women destined to develop preeclampsia". Hypertens Pregnancy. 2014 Nov; 33(4):525.
    View in: PubMed
    Score: 0.346
  33. Placental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia. Hypertens Pregnancy. 2014 Nov; 33(4):427-39.
    View in: PubMed
    Score: 0.345
  34. Angiogenic factors in preeclampsia: potential for diagnosis and treatment. Curr Opin Nephrol Hypertens. 2013 Nov; 22(6):643-50.
    View in: PubMed
    Score: 0.328
  35. Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension. 2014 Feb; 63(2):198-202.
    View in: PubMed
    Score: 0.328
  36. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy. 2013 May; 32(2):189-201.
    View in: PubMed
    Score: 0.317
  37. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One. 2012; 7(10):e48259.
    View in: PubMed
    Score: 0.306
  38. Circulating lymphangiogenic factors in preeclampsia. Hypertens Pregnancy. 2013; 32(1):42-9.
    View in: PubMed
    Score: 0.303
  39. Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension. 2012 Aug; 60(2):451-8.
    View in: PubMed
    Score: 0.299
  40. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012 Feb 21; 125(7):911-9.
    View in: PubMed
    Score: 0.290
  41. Placental origins of angiogenic dysfunction in mirror syndrome. Hypertens Pregnancy. 2012; 31(2):211-7.
    View in: PubMed
    Score: 0.288
  42. Physicians' knowledge of future vascular disease in women with preeclampsia. Hypertens Pregnancy. 2012; 31(1):50-8.
    View in: PubMed
    Score: 0.272
  43. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am. 2010 Jun; 37(2):239-53.
    View in: PubMed
    Score: 0.259
  44. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007 Jul; 50(1):137-42.
    View in: PubMed
    Score: 0.210
  45. Cytomegalovirus-induced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet Gynecol. 2007 Feb; 109(2 Pt2):549-52.
    View in: PubMed
    Score: 0.206
  46. Neuropsychological performance in normal pregnancy and preeclampsia. Am J Obstet Gynecol. 2006 Jul; 195(1):186-91.
    View in: PubMed
    Score: 0.194
  47. Impact of PlGF immunoassay imprecision on preeclampsia risk assessment with the sFlt-1 to PlGF ratio. Am J Clin Pathol. 2025 Aug 26; 164(2):200-206.
    View in: PubMed
    Score: 0.186
  48. Reference Range Determination for the sFlt-1/PlGF Ratio in a Diverse Cohort of Pregnant Women in the United States. J Appl Lab Med. 2025 Jul 01; 10(4):937-948.
    View in: PubMed
    Score: 0.184
  49. Effect of postpartum oral furosemide use on postpartum readmissions and blood pressure trends. Pregnancy Hypertens. 2025 Mar; 39:101199.
    View in: PubMed
    Score: 0.179
  50. Plasma soluble fms-like tyrosine kinase 1 to placental growth factor ratio of 11.5 multiples of median predicts preeclampsia with severe features within 2 weeks of testing. Am J Obstet Gynecol. 2024 Sep; 231(3):363.e1-363.e11.
    View in: PubMed
    Score: 0.171
  51. Placental senescence pathophysiology is shared between peripartum cardiomyopathy and preeclampsia in mouse and human. Sci Transl Med. 2024 04 17; 16(743):eadi0077.
    View in: PubMed
    Score: 0.170
  52. Association of activin A and postpartum blood pressure in peripartum cardiomyopathy. Pregnancy Hypertens. 2023 Dec; 34:60-66.
    View in: PubMed
    Score: 0.164
  53. Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy. NEJM Evid. 2022 Dec; 1(12):EVIDoa2200161.
    View in: PubMed
    Score: 0.153
  54. The additive role of angiogenic markers for women with confirmed preeclampsia. Am J Obstet Gynecol. 2023 05; 228(5):573.e1-573.e11.
    View in: PubMed
    Score: 0.153
  55. Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertens. 2022 Mar; 27:42-50.
    View in: PubMed
    Score: 0.144
  56. Is Prolonging Gestation in Preeclampsia For Better or Worse in Preventing Cardiovascular Disease? Hypertension. 2021 11; 78(5):1395-1397.
    View in: PubMed
    Score: 0.142
  57. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022 Mar; 27:148-169.
    View in: PubMed
    Score: 0.142
  58. Angiogenic factors and prediction for ischemic placental disease in future pregnancies. Pregnancy Hypertens. 2021 Aug; 25:12-17.
    View in: PubMed
    Score: 0.138
  59. Long-Term Postpartum Cardiac Function and Its Association With Preeclampsia. J Am Heart Assoc. 2021 02; 10(5):e018526.
    View in: PubMed
    Score: 0.136
  60. Antepartum Aspirin Administration Reduces Activin A and Cardiac Global Longitudinal Strain in Preeclamptic Women. J Am Heart Assoc. 2020 06 16; 9(12):e015997.
    View in: PubMed
    Score: 0.130
  61. Analytical validation of soluble fms-like tyrosine and placental growth factor assays on B·R·A·H·M·S KRYPTOR Compact Plus automated immunoassay platform. Pregnancy Hypertens. 2018 Jan; 11:66-70.
    View in: PubMed
    Score: 0.110
  62. Gelsolin is an endogenous inhibitor of syncytiotrophoblast extracellular vesicle shedding in pregnancy. Pregnancy Hypertens. 2016 Oct; 6(4):333-339.
    View in: PubMed
    Score: 0.099
  63. Trophoblast mitochondrial function is impaired in preeclampsia and correlates negatively with the expression of soluble fms-like tyrosine kinase 1. Pregnancy Hypertens. 2016 Oct; 6(4):313-319.
    View in: PubMed
    Score: 0.099
  64. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol. 2016 Jan; 214(1):108.e1-108.e14.
    View in: PubMed
    Score: 0.094
  65. Epidemiology and Mechanisms of De Novo and Persistent Hypertension in the Postpartum Period. Circulation. 2015 Nov 03; 132(18):1726-33.
    View in: PubMed
    Score: 0.094
  66. The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes. Hypertens Pregnancy. 2014 Feb; 33(1):81-92.
    View in: PubMed
    Score: 0.083
  67. Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1. Hypertens Pregnancy. 2014 May; 33(2):250-9.
    View in: PubMed
    Score: 0.083
  68. The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. J Perinat Med. 2013 Sep 01; 41(5):511-6.
    View in: PubMed
    Score: 0.081
  69. Subclinical left ventricular dysfunction in preeclamptic women with preserved left ventricular ejection fraction: a 2D speckle-tracking imaging study. Circ Cardiovasc Imaging. 2012 Nov; 5(6):734-9.
    View in: PubMed
    Score: 0.075
  70. Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension. 2012 Feb; 59(2):256-64.
    View in: PubMed
    Score: 0.072
  71. Preeclampsia and the risk of large-for-gestational-age infants. Am J Obstet Gynecol. 2011 May; 204(5):425.e1-6.
    View in: PubMed
    Score: 0.068
  72. First trimester vitamin D, vitamin D binding protein, and subsequent preeclampsia. Hypertension. 2010 Oct; 56(4):758-63.
    View in: PubMed
    Score: 0.066
  73. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda). 2009 Jun; 24:147-58.
    View in: PubMed
    Score: 0.060
  74. Circulating soluble endoglin and placental abruption. Prenat Diagn. 2008 Sep; 28(9):852-8.
    View in: PubMed
    Score: 0.057
  75. Use of circulating antiangiogenic factors to differentiate other hypertensive disorders from preeclampsia in a pregnant woman on dialysis. Am J Kidney Dis. 2008 Jun; 51(6):1029-32.
    View in: PubMed
    Score: 0.056
  76. Circulating levels of the antiangiogenic marker soluble FMS-like tyrosine kinase 1 are elevated in women with pregestational diabetes and preeclampsia: angiogenic markers in preeclampsia and preexisting diabetes. Diabetes Care. 2007 Feb; 30(2):375-7.
    View in: PubMed
    Score: 0.051
  77. Report from a text-based blood pressure monitoring prospective cohort trial among postpartum women with hypertensive disorders of pregnancy. BMC Pregnancy Childbirth. 2024 May 03; 24(1):340.
    View in: PubMed
    Score: 0.043
  78. Luteolin-induced vasorelaxation in uterine arteries from normal pregnant rats. Pregnancy Hypertens. 2021 Mar; 23:11-17.
    View in: PubMed
    Score: 0.033
  79. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012 May 09; 485(7398):333-8.
    View in: PubMed
    Score: 0.019
  80. Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery. J Matern Fetal Neonatal Med. 2012 Jul; 25(7):1135-41.
    View in: PubMed
    Score: 0.018
  81. Role of oxidative stress and antioxidant supplementation in pregnancy disorders. Am J Clin Nutr. 2011 Dec; 94(6 Suppl):1980S-1985S.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.